FOXO3 and colonic neoplasm: Previous research has shown that Selumetinib (AZD6244) increases FOXO3A expression and inhibits the proliferation of colon cancer cells, and FOXO3A has also been found to increase cancer cells’ sensitivity to radiation [64, 65].